Emcure Pharmaceuticals IPO GMP History
Emcure Pharmaceuticals IPO has been listed on July 10, 2024 at a listing price of ₹1325.05, against the issue price of ₹1008 — a gain of ₹317.05 (+31.45%). The GMP peaked at ₹365 on 8 July 2024 and reached a low of ₹250 on 29 June 2024. The day-wise GMP trend below shows how grey market sentiment evolved from subscription to listing.
Emcure Pharmaceuticals IPO raised ₹1952.03 Cr. through its IPO at a price band of ₹960 to ₹1008 per share, with a lot size of 14 shares. The IPO was open for subscription from 03 Jul 2024 to 05 Jul 2024.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
GMP trend
Grey market premium sampled three times a day (11 AM, 5 PM, 10 PM). Last updated 10 Nov, 6:45 PM IST.
Day-wise GMP
The last reading of each day, newest first. Arrows compare with the previous day.
| Date | GMP | ↑↓ | % | Kostak | Sub. Sauda |
|---|---|---|---|---|---|
| 09 Jul 2024 | ₹ 360 | ▼ | 36% | — | — |
| 08 Jul 2024 | ₹ 365 | ▲ | 36% | — | — |
| 06 Jul 2024 | ₹ 355 | ▲ | 35% | — | — |
| 05 Jul 2024 | ₹ 320 | ▲ | 32% | — | — |
| 04 Jul 2024 | ₹ 310 | ▲ | 31% | — | — |
| 03 Jul 2024 | ₹ 282 | ▲ | 28% | — | — |
| 02 Jul 2024 | ₹ 275 | ▲ | 27% | — | — |
| 01 Jul 2024 | ₹ 260 | ▲ | 26% | — | — |
| 29 Jun 2024 | ₹ 250 | — | 25% | — | — |
Emcure Pharmaceuticals IPO dates
Key dates from opening to listing. Today is 11 November.
- Open 03 Jul 2024
- Close 05 Jul 2024
- Allotment 08 Jul 2024
- Refund/credit 09 Jul 2024
- Listing 10 Jul 2024
Emcure Pharmaceuticals IPO actual listing price
How the grey market's final call compared with the listing-day open.
| Issue price | ₹1008 |
|---|---|
| GMP-based estimate (pre-listing) | ₹1368 (+35.7%) |
| Listing gain / loss | +₹317.05 per share |
| Listing date | 10 Jul, 2024 |
| Actual listing price | ₹1325.05 (+31.45%) |
Is Emcure Pharmaceuticals IPO GMP reliable?
Grey market premium for Emcure Pharmaceuticals IPO should be interpreted with caution. The GMP is an unregulated, unofficial market not governed by SEBI. Here's how to read the current signal:
- 01Subscription rate matters: A high GMP paired with strong subscription — especially QIB (Qualified Institutional Buyer) oversubscription — is a more reliable bullish signal than GMP alone. Read our in-depth analysis: GMP vs Subscription Data — Which Predicts Listing Gains Better?
- 02Timing matters: GMP in the first 1–2 days of subscription is less reliable. GMP on the final subscription day and the day before listing tends to be the most accurate predictor.
- 03Grey market is thin: For smaller IPOs, even a handful of large orders can swing the GMP significantly. Treat low-volume GMP signals with extra caution.
- 04Cross-check before acting: Review the Emcure Pharmaceuticals IPO full review for a fundamentals-based assessment before making any grey market trades.
Emcure Pharmaceuticals IPO Kostak rate explained
Two ways the grey market trades an IPO application before listing.
The Kostak rate for Emcure Pharmaceuticals IPO was not available during the subscription period. Kostak is the fixed amount a grey market buyer pays for an IPO application regardless of allotment outcome.
The Subject to Sauda price was not available for this IPO. Subject to Sauda only applies if allotment is confirmed — the buyer pays a premium on top of the issue price per lot allotted.
Grey market trading is unofficial and unregulated by SEBI. Proceed with full awareness of the associated risks.
About Emcure Pharmaceuticals IPO
Emcure Pharmaceuticals Limited was incorporated as Emcure Pharmaceuticals Private Limited on 16 April 1981. It is an Indian pharmaceutical company that develops, makes and markets a broad range of products across major therapy areas.
It is research driven, with a portfolio of orals, injectables and biotherapeutics that reaches over 70 countries, with a strong presence in India, Europe and Canada.
In India it works across acute and chronic therapy areas, including gynaecology, cardiovascular, vitamins and minerals and HIV antivirals. Its promoters include Satish Ramanlal Mehta, Sunil Rajanikant Mehta, Namita Vikas Thapar and Samit Satish Mehta.
The IPO was Rs 1,952.03 crore, with Rs 800.58 crore of fresh issue and Rs 1,151.45 crore of offer for sale, mostly by BC Investments IV, with promoters and promoter group members also selling. Rs 800.00 crore was planned for repaying borrowings.
Frequently asked
What is the GMP of Emcure Pharmaceuticals IPO?
The current Grey Market Premium (GMP) of Emcure Pharmaceuticals IPO is ₹ 360.
What is the Kostak Price of Emcure Pharmaceuticals IPO?
Kostak rate is the profit made by selling an IPO application before allotment. The current Kostak rate for Emcure Pharmaceuticals IPO is not available.
What is the Subject to Sauda Price of Emcure Pharmaceuticals IPO?
Subject to Sauda is the premium amount decided if the allotment is confirmed. The current Subject to Sauda rate is not available.
What was the actual listing price of Emcure Pharmaceuticals IPO?
Emcure Pharmaceuticals IPO listed on July 10, 2024 at ₹1325.05, against the issue price of ₹1008 — a gain of +31.45%.
How did the GMP of Emcure Pharmaceuticals IPO trend before listing?
The GMP of Emcure Pharmaceuticals IPO was falling in its final days before listing. The GMP peaked at ₹365 on 8 July 2024. View the day-wise table above for the complete GMP history.
Explore Emcure Pharmaceuticals IPO further
The grey market is one signal. Read it alongside the demand, the reviews and the filings before you decide.
It has listed — go back to the fundamentals.
Category-wise demand from QIB, NII and retail investors, updated through the day.
What brokers and analysts are saying about this issue, in one place.
Check with your PAN whether shares were credited to your demat account.
The grey market called it. Now check the fundamentals.
IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Read the grey market alongside the subscription book and the offer document before you apply.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
